Skip to main content

Terns Pharmaceuticals, Inc.

TERNDelisted
Industry
Pharmaceutical Preparations
SEC CIK
0001831363

Terns Pharmaceuticals, Inc. was delisted in 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Terns Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Terns Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Terns Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Fellows David ADirector–May 5, 20262
Kindler Jeffrey BDirector–May 5, 20262
Turner Heather DDirector–May 5, 20262
Gengos AndrewChief Financial Officer0May 5, 20262
Azelby RobertDirector–May 5, 20262
Tripuraneni RadhikaDirector–May 5, 20262
Quigley Jill M.Director0May 5, 20263
Burroughs Amy L.Chief Executive Officer0May 5, 20265
Kuriakose EmilChief Medical Officer0May 5, 20265
Lu HongboDirector476,190IndirectJun 12, 20250
Jung Melita SunChief Business Officer2,250Feb 3, 20250
Vignola Mark J.Chief Financial Officer74,752Jan 6, 20250
OrbiMed Advisors LLCDirector, 10% Owner755,635IndirectJul 17, 20240
OrbiMed Capital GP VII LLCDirector, 10% Owner755,635IndirectJul 17, 20240
OrbiMed Genesis GP LLCDirector, 10% Owner755,635IndirectJul 17, 20240
OrbiMed Asia GP III, L.P.Director, 10% Owner755,635IndirectJul 17, 20240
OrbiMed Advisors III LtdDirector, 10% Owner755,635IndirectJul 17, 20240
Gordon Carl LDirector, 10% Owner755,635IndirectJul 17, 20240
Taylor Ann ElizabethDirector–Jul 2, 20240
Yoon Seokho BryanCOO and General Counsel91,940Jun 4, 20240
Vivo Capital Fund VIII, L.P.10% Owner268,573IndirectApr 3, 20240
Vivo Capital VIII, LLC10% Owner268,573IndirectApr 3, 20240
Vivo Capital Surplus Fund VIII, L.P.10% Owner268,573IndirectApr 3, 20240
Vivo Opportunity, LLC10% Owner268,573IndirectApr 3, 20240
Vivo Opportunity Fund Holdings, L.P.10% Owner268,573IndirectApr 3, 20240
Quirk ErinPresident, Head of R&D75,000Jan 25, 20240
Sundaram Senthil VelChief Executive Officer9,770Jun 2, 20230
LAV Biosciences Fund V, L.P.10% Owner529,762IndirectNov 28, 20220
Oriental Spring Venture Ltd10% Owner529,762IndirectNov 28, 20220
Hopewell Resources Holdings Ltd10% Owner529,762IndirectNov 28, 20220
LAV Aqua Ltd10% Owner529,762IndirectNov 28, 20220
Russell Kerry StrongChief Medical Officer–Jul 6, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Apr 2, 2026 (view filing)Apr 11 dayKuriakose EmilChief Medical OfficerSSale−942$52.75−$49.7K−0.9%105.7K after
Mar 17, 2026 (view filing)Mar 161 dayBurroughs Amy L.Chief Executive OfficerSSale−14.6K$46.71−$681.2K−4.8%289.0K after2 lots10b5-1
Feb 18, 2026 (view filing)Feb 171 dayBurroughs Amy L.Chief Executive OfficerSSale−14.6K$39.20−$571.6K−4.8%289.0K after3 lots10b5-1
Jan 16, 2026 (view filing)Jan 151 dayBurroughs Amy L.Chief Executive OfficerSSale−68.7K$37.08−$2.55M−19.2%289.0K after2 lots10b5-1
Jan 6, 2026 (view filing)Jan 24 daysKuriakose EmilChief Medical OfficerSSale−1.16K$38.57−$44.6K−2.2%50.4K after2 lots
Jan 6, 2026 (view filing)Jan 51 dayBurroughs Amy L.Chief Executive OfficerSSale−71.3K$38.10−$2.72M−33.9%139.0K after
Nov 5, 2025 (view filing)Nov 41 dayQuigley Jill M.DirectorSSale−24.5K$18.00−$441.4K−100.0%0 after10b5-1
Oct 2, 2025 (view filing)Oct 11 dayKuriakose EmilChief Medical OfficerSSale−944$7.85−$7.41K−1.8%51.5K after
Jul 3, 2025 (view filing)Jul 12 daysKuriakose EmilChief Medical OfficerSSale−853$4.27−$3.64K−1.6%52.5K after
Jun 30, 2025 (view filing)Jun 273 daysGengos AndrewChief Financial OfficerPPurchase+10.0K$3.93+$39.3K+66.7%25.0K after2 lots
Jun 25, 2025 (view filing)Jun 25Same dayBurroughs Amy L.Chief Executive OfficerPPurchase+23.3K$3.87+$90.2K+98.1%47.1K after
Jun 16, 2025 (view filing)Jun 13-163 daysGengos AndrewChief Financial OfficerPPurchase+15.0K$3.81+$57.1KNew position15.0K after3 lots
Apr 2, 2025 (view filing)Apr 11 dayKuriakose EmilChief Medical OfficerSSale−952$2.49−$2.37K−1.8%53.3K after
Feb 3, 2025 (view filing)Nov 30, 202465 daysLateJung Melita SunChief Business OfficerPPurchase+2.25K$5.11+$11.5KNew position2.25K after
Feb 3, 2025 (view filing)Nov 30, 202465 daysLateBurroughs Amy L.Chief Executive OfficerPPurchase+510$5.11+$2.61K+2.7%19.6K after
Jan 6, 2025 (view filing)Jan 24 daysKuriakose EmilChief Medical OfficerSSale−4.48K$5.71−$25.6K−7.6%54.3K after
Jan 6, 2025 (view filing)Jan 2-64 daysVignola Mark J.Chief Financial OfficerSSale−17.2K$5.76−$99.0K−18.7%74.8K after2 lots10b5-1
Jan 6, 2025 (view filing)Jan 2-64 daysQuigley Jill M.DirectorSSale−15.0K$5.76−$86.4K−100.0%0 after2 lots10b5-1
Dec 9, 2024 (view filing)Dec 54 daysBurroughs Amy L.Chief Executive OfficerPPurchase+15.4K$7.15+$110.5K+423.4%19.1K after
Sep 17, 2024 (view filing)Sep 125 daysLateLu HongboDirectorPPurchase+476.2K$10.50+$5.00MNew position476.2K after2 lots
Sep 12, 2024 (view filing)Sep 102 daysVignola Mark J.Chief Financial OfficerSSale−10.0K$11.00−$110.0K−9.8%91.9K after10b5-1
Sep 11, 2024 (view filing)Sep 92 daysQuigley Jill M.DirectorSSale−17.2K$10.00−$172.3K−53.5%15.0K after10b5-1
Aug 5, 2024 (view filing)Aug 1-24 daysQuigley Jill M.DirectorSSale−15.0K$7.57−$113.6K−50.0%15.0K after2 lots10b5-1
Jul 17, 2024 (view filing)8:48 PM ETJul 15-162 daysOrbiMed Advisors LLC and 4 othersDirector, 10% OwnerSSale−56.2K$10.00−$561.6K−6.9%755.6K after6 lots10b5-1Duplicate filing
Jul 17, 2024 (view filing)Jul 15-162 daysQuigley Jill M.DirectorSSale−14.8K$10.00−$147.7K−33.0%30.0K after2 lots10b5-1
Jul 17, 2024 (view filing)Jul 15-162 daysGordon Carl LDirector, 10% OwnerSSale−56.2K$10.00−$561.6K−6.9%755.6K after6 lots10b5-1
Jun 4, 2024 (view filing)May 314 daysYoon Seokho BryanCOO and General CounselPPurchase+4.79K$4.44+$21.3K+5.5%91.9K after
Jun 4, 2024 (view filing)May 314 daysVignola Mark J.Chief Financial OfficerPPurchase+4.79K$4.44+$21.3K+5.5%91.9K after
Apr 3, 2024 (view filing)8:47 PM ETApr 1-32 daysVivo Capital Fund VIII, L.P. and 4 others10% OwnerSSale−420.7K$6.65−$2.80M−61.0%268.6K after9 lots10b5-1
Dec 4, 2023 (view filing)Nov 304 daysYoon Seokho BryanCOO and General CounselPPurchase+743$3.78+$2.81K+4.2%18.4K after
Dec 4, 2023 (view filing)Nov 304 daysVignola Mark J.Chief Financial OfficerPPurchase+743$3.78+$2.81K+4.2%18.4K after
Jun 2, 2023 (view filing)May 312 daysVignola Mark J.Chief Financial OfficerPPurchase+10.0K$1.41+$14.1K+130.5%17.7K after
Jun 2, 2023 (view filing)May 312 daysYoon Seokho BryanCOO and General CounselPPurchase+10.0K$1.41+$14.1K+130.5%17.7K after
Jun 2, 2023 (view filing)May 312 daysSundaram Senthil VelChief Executive OfficerPPurchase+2.11K$1.41+$2.98K+27.6%9.77K after
Feb 3, 2023 (view filing)Nov 30, 202265 daysLateYoon Seokho BryanCOO and General CounselPPurchase+3$1.41+$4.230.0%7.66K after
Feb 3, 2023 (view filing)Nov 30, 202265 daysLateVignola Mark J.Chief Financial OfficerPPurchase+3$1.41+$4.230.0%7.66K after
Feb 3, 2023 (view filing)Nov 30, 202265 daysLateSundaram Senthil VelChief Executive OfficerPPurchase+3$1.41+$4.230.0%7.66K after
Dec 28, 2022 (view filing)5:57 PM ETDec 235 daysOrbiMed Advisors LLC and 4 othersDirector, 10% OwnerPPurchase+137.9K$7.25+$1.00M+2.9%4.88M afterDuplicate filing
Dec 28, 2022 (view filing)Dec 235 daysGordon Carl LDirector, 10% OwnerPPurchase+137.9K$7.25+$1.00M+2.9%4.88M after
Dec 23, 2022 (view filing)5:48 PM ETDec 23Same dayVivo Capital Fund VIII, L.P. and 4 others10% OwnerPPurchase+758.6K$7.25+$5.50M+21.2%4.34M afterDuplicate filing
Dec 23, 2022 (view filing)Dec 23Same dayLu HongboDirectorPPurchase+758.6K$7.25+$5.50M+21.2%4.34M after
Nov 28, 2022 (view filing)4:56 PM ETNov 235 daysLAV Biosciences Fund V, L.P. and 3 others10% OwnerSSale−1.50M$5.50−$8.25M−73.9%529.8K after3 lots
Sep 8, 2022 (view filing)8:00 PM ETSep 71 dayVivo Capital Fund VIII, L.P. and 4 others10% OwnerPPurchase+600.0K$3.60+$2.16M+20.1%3.58M afterDuplicate filing
Sep 8, 2022 (view filing)Sep 71 dayLu HongboDirectorPPurchase+600.0K$3.60+$2.16M+20.1%3.58M after
Aug 18, 2022 (view filing)5:00 PM ETAug 162 daysOrbiMed Advisors LLC and 4 othersDirector, 10% OwnerPPurchase+3.69M$2.42+$8.93MNew position762.4K after3 lotsDuplicate filing
Aug 18, 2022 (view filing)5:00 PM ETAug 162 daysOrbiMed Advisors LLC and 4 othersDirector, 10% OwnerPPurchase+310.0K–––64.0K afterDerivative3 lotsDuplicate filing
Aug 18, 2022 (view filing)Aug 162 daysGordon Carl LDirector, 10% OwnerPPurchase+3.69M$2.42+$8.93MNew position762.4K after3 lots
Aug 18, 2022 (view filing)Aug 162 daysGordon Carl LDirector, 10% OwnerPPurchase+310.0K–––64.0K afterDerivative3 lots
Aug 16, 2022 (view filing)8:44 PM ETAug 12-164 daysVivo Capital Fund VIII, L.P. and 4 others10% OwnerPPurchase+2.62M$2.66+$6.98M+734.4%2.98M after3 lotsDuplicate filing
Aug 16, 2022 (view filing)8:44 PM ETAug 16Same dayVivo Capital Fund VIII, L.P. and 4 others10% OwnerPPurchase+1.50M$2.42+$3.63M–1.50M afterDerivative